Literature DB >> 3819647

Guinea pigs sublethally infected with aerosolized Legionella pneumophila develop humoral and cell-mediated immune responses and are protected against lethal aerosol challenge. A model for studying host defense against lung infections caused by intracellular pathogens.

R F Breiman, M A Horwitz.   

Abstract

We have employed the guinea pig model of L. pneumophila infection, which mimics Legionnaires' disease in humans both clinically and pathologically, to study humoral and cell-mediated immune responses to L. pneumophila and to examine protective immunity after aerosol exposure, the natural route of infection. Guinea pigs exposed to sublethal concentrations of L. pneumophila by aerosol developed strong humoral immune responses. By the indirect fluorescent antibody assay, exposed guinea pigs had a median serum antibody titer (expressed as the reciprocal of the highest positive dilution) of 32, whereas control guinea pigs had a median titer of less than 1. Sublethally infected (immunized) guinea pigs also developed strong cell-mediated immune responses. In response to L. pneumophila antigens, splenic lymphocytes from immunized but not control animals proliferated strongly in vitro, as measured by their capacity to incorporate [3H]thymidine. Moreover, immunized but not control guinea pigs developed strong cutaneous delayed-type hypersensitivity to intradermally injected L. pneumophila antigens. Sublethally infected (immunized) guinea pigs exhibited strong protective immunity to L. pneumophila. In two independent experiments, all 22 immunized guinea pigs survived aerosol challenge with one or three times the lethal dose of L. pneumophila whereas none of 16 sham-immunized control guinea pigs survived (p less than 0.0001 in each experiment). Immunized guinea pigs were not protected significantly from challenge with 10 times the lethal dose. Immunized but not control animals cleared the bacteria from their lungs. This study demonstrates that guinea pigs sublethally infected with L. pneumophila by the aerosol route develop strong humoral immune responses to this pathogen, develop strong cell-mediated immune responses and cutaneous delayed-type hypersensitivity to L. pneumophila antigens, are protected against subsequent lethal aerosol challenge, and are able to clear the bacteria from their lungs. The guinea pig model of L. pneumophila pulmonary infection is as an excellent one for studying general principles of host defense against pulmonary infections caused by intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3819647      PMCID: PMC2188290          DOI: 10.1084/jem.165.3.799

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Vaccination against Legionella pneumophila: serum antibody correlates with protection induced by heat-killed or acetone-killed cells against intraperitoneal but not aerosol infection in guinea pigs.

Authors:  T K Eisenstein; R Tamada; J Meissler; A Flesher; H C Oels
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

2.  Experimental transmission of legionnaires' disease by exposure to aerosols of Legionella pneumophila.

Authors:  A Baskerville; R B Fitzgeorge; M Broster; P Hambleton; P J Dennis
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

3.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

4.  Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

5.  Dose-response of guinea pigs experimentally infected with aerosols of Legionella pneumophila.

Authors:  R F Berendt; H W Young; R G Allen; G L Knutsen
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

6.  Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

7.  Indirect immunofluorescence test for serodiagnosis of Legionnaires disease: evidence for serogroup diversity of Legionnaires disease bacterial antigens and for multiple specificity of human antibodies.

Authors:  H W Wilkinson; B J Fikes; D D Cruce
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

8.  Interaction of the Legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. I. L. pneumophila resists killing by polymorphonuclear leukocytes, antibody, and complement.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

9.  Interaction between the legionnaires' disease bacterium (Legionella pneumophila) and human alveolar macrophages. Influence of antibody, lymphokines, and hydrocortisone.

Authors:  T W Nash; D M Libby; M A Horwitz
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  Interaction of the legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. II. Antibody promotes binding of L. pneumophila to monocytes but does not inhibit intracellular multiplication.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more
  21 in total

1.  Difference in the induction of macrophage interleukin-1 production between viable and killed cells of Listeria monocytogenes.

Authors:  M Mitsuyama; K Igarashi; I Kawamura; T Ohmori; K Nomoto
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

2.  Hypoexpression of major histocompatibility complex molecules on Legionella pneumophila phagosomes and phagolysosomes.

Authors:  D L Clemens; M A Horwitz
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

3.  An immunoprotective molecule, the major secretory protein of Legionella pneumophila, is not a virulence factor in a guinea pig model of Legionnaires' disease.

Authors:  S J Blander; L Szeto; H A Shuman; M A Horwitz
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Legionella pneumophila htpAB heat shock operon: nucleotide sequence and expression of the 60-kilodalton antigen in L. pneumophila-infected HeLa cells.

Authors:  P S Hoffman; L Houston; C A Butler
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

5.  Macrophage-activating T-cell factor(s) produced in an early phase of Legionella pneumophila infection in guinea pigs.

Authors:  Y Nikaido; S Yoshida; Y Goto; Y Mizuguchi; A Kuroiwa
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

Review 6.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

7.  Identification of a Legionella pneumophila locus required for intracellular multiplication in human macrophages.

Authors:  A Marra; S J Blander; M A Horwitz; H A Shuman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Major cytoplasmic membrane protein of Legionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease.

Authors:  S J Blander; M A Horwitz
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis.

Authors:  P G Pal; M A Horwitz
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Human and guinea pig immune responses to Legionella pneumophila protein antigens OmpS and Hsp60.

Authors:  R Weeratna; D A Stamler; P H Edelstein; M Ripley; T Marrie; D Hoskin; P S Hoffman
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.